Lv7
3340 积分 2021-09-07 加入
2023 FDA approvals
12天前
已完结
FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit
12天前
已完结
Trends in the approval of cancer therapies by the FDA in the twenty-first century
12天前
已完结
Biomarkers for Precision Patient Selection in Cancer Therapy Approvals in the US, from 2011 to 2023
13天前
已完结
Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021
13天前
已完结
Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification
23天前
已完结
NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned
27天前
已完结
Biomarkers and biomarker validation: a pathologist's guide to getting it right
27天前
已完结
Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020
27天前
已完结
To Be, or Not To Be … a Biomarker? A Question to the FDA
27天前
已完结
皖公网安备34019202002308
